Tier 2 — strong

A Randomized Placebo-controlled Double Blind Clinical Trial of Quercetin for Treatment of Oral Lichen Planus

Maryam Amirchaghmaghi, Zahra Delavarian, Mehrdad Iranshahi, Mohammad Taghi Shakeri, Pegah Mosannen Mozafari, Amir Hushang Mohammadpour, Fatemeh Farazi, Milad Iranshahy
Journal of dental research, dental clinics, dental prospects 2015 9(1):23

Bibliography

PubMed
PMID 25973150
PubMed Central
PMC4417489
DOI
10.15171/joddd.2015.005
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled adjunctive trial
ModelHuman intervention research
Sample30 adults with erosive-atrophic oral lichen planus
InterventionQuercetin hydrate 250 mg twice daily or placebo, alongside dexamethasone and nystatin
DurationClinical follow-up; exact dosing duration requires full methods
EndpointsSymptoms and quality of life

What the study showed, in plain terms

Published in 2015, this source examined skin and topical formulations. Design: Randomized double-blind placebo-controlled adjunctive trial. Sample/model: 30 adults with erosive-atrophic oral lichen planus. The exposure or intervention was Quercetin hydrate 250 mg twice daily or placebo, alongside dexamethasone and nystatin. Follow-up or treatment period: Clinical follow-up; exact dosing duration requires full methods.

Lesion severity and pain did not differ significantly between groups.

Within-group symptom improvement does not establish added benefit over placebo and standard treatment.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Skin and Hair: Oral vs Topical Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Lesion severity and pain did not differ significantly between groups.
  • The recorded outcome domains were Symptoms and quality of life.
  • The result applies to the tested exposure: Quercetin hydrate 250 mg twice daily or placebo, alongside dexamethasone and nystatin; Clinical follow-up; exact dosing duration requires full methods.

What this study can and cannot tell us

  • Within-group symptom improvement does not establish added benefit over placebo and standard treatment.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin as a Natural Adjunct in Managing Plaque and Gingivitis in Adults: A Randomized Controlled Trial
Ankita Rawal et al. · Cureus · 2026
Tier 2
Efficacy and Safety of Topical Compound Heparin Sodium Allantoin Gel (Main Components: Onion Extract Quercetin) for the Treatment of Rosacea
Zining Xu et al. · Journal of cosmetic dermatology · 2025
Tier 2
Quercetin loaded cosm-nutraceutical electrospun composite nanofibers for acne alleviation: Preparation, characterization and experimental clinical appraisal
Sandra Sherif Amer et al. · International journal of pharmaceutics · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology